Drug Approval | February 20, 2022
Poxel’s PXL065 granted FDA fast track designation for X-linked adrenoleukodystrophy
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Adds five years of market exclusivity on approval
The FDA grants ODD status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect fewer than 200,000 people in the US
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
ZY19489 is a novel anti-malarial compound active against all current clinical strains of P. falciparum and P. vivax, including drug resistant strains
GCC Biotech is manufacturing the kits on a public-private partnership (PPP) model
Theradaptive's regenerative implants are best-in-class and are designed to permit precise tissue regeneration for a variety of tissue types and clinical indications
Subscribe To Our Newsletter & Stay Updated
